The latest medical insurance reimbursement policy for osimertinib (Tagressa) in 2024

Osimertinib is an oral targeted therapy drug that is a third-generation epidermal growth factor receptor (EGFR) inhibitor. It is designed to treat advanced non-small cell lung cancer (NSCLC), specifically those with EGFR mutations, including common EGFR activating mutations and drug-resistant mutations such as T790M.

Osimertinib has now entered the Chinese market and has also been included in the medical insurance system. Therefore, patients can easily purchase it in domestic hospital pharmacies, and the price remains in the range of four to five thousand yuan. However, you still need to consult the local hospital pharmacy for detailed consultation on the specific amount and medical insurance reimbursement details.

In addition, if you are looking for a more economical option, foreign generic drugs of osimertinib may be a good choice. In particular, generic drugs produced in Laos and Bangladesh are affordable and only cost a few hundred yuan, which has a significant price advantage compared to domestic versions. More importantly, the ingredients of these generic drugs are highly consistent with the domestic original drugs.

Compared with traditionalEGFR inhibitors, osimertinib has higher selectivity and stronger anti-tumor activity. It blocks the activation of tumor cell signaling pathways by specifically inhibiting EGFR kinase activity, thereby inhibiting the growth and spread of tumor cells.

The efficacy of osimertinib has been fully verified in clinical trials. Studies have shown that osimertinib can significantly extend progression-free survival (PFS), improve overall survival, and is generally associated with lower toxicity. One of its particularly outstanding advantages is its effectiveness against the common EGFR T790M resistance mutation, a problem that many other treatments do not address well.

As an oral drug, osimertinib is easy to use and can be taken easily by patients at home without the need for lengthy hospital stays. This allows patients to better maintain quality of life while receiving effective treatment.